These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29381689)

  • 1. Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
    Antonio M; Saldaña J; Linares J; Ruffinelli JC; Palmero R; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Navarro V; González-Barboteo J; Borràs JM; Cardenal F; Nadal E
    Br J Cancer; 2018 Mar; 118(5):639-647. PubMed ID: 29381689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).
    Locher C; Pourel N; Le Caer H; Berard H; Auliac JB; Monnet I; Descourt R; Vergnenègre A; Lafay IM; Greillier L; Chouaïd C
    Lung Cancer; 2018 Jul; 121():25-29. PubMed ID: 29858022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making?
    Antonio M; Saldaña J; Carmona-Bayonas A; Navarro V; Tebé C; Nadal M; Formiga F; Salazar R; Borràs JM
    Oncologist; 2017 Aug; 22(8):934-943. PubMed ID: 28487465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
    BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
    Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
    Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study.
    Antonio M; Carmona-Bayonas A; Saldaña J; Navarro V; Tebé C; Salazar R; Borràs JM
    Clin Colorectal Cancer; 2018 Mar; 17(1):e59-e68. PubMed ID: 29054805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer.
    Ma H; Peng F; Xu Y; Bao Y; Hu X; Wang J; Fang M; Kong Y; Dong B; Chen M
    Ann Palliat Med; 2021 Jul; 10(7):7560-7570. PubMed ID: 34353044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-small cell lung cancer irradiation in elderly].
    Dupic G; Bellière-Calandry A
    Cancer Radiother; 2016 Jun; 20(4):322-9. PubMed ID: 27342942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
    Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G
    Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
    Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
    Takase N; Hattori Y; Kiriu T; Itoh S; Kawa Y; Yamamoto M; Urata Y; Shimada T; Tsujino K; Soejima T; Negoro S; Satouchi M
    Respir Investig; 2016 Sep; 54(5):334-40. PubMed ID: 27566381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity.
    Almodovar T; Teixeira E; Barroso A; Soares M; Queiroga HJ; Cavaco-Silva J; Barata F
    Pulmonology; 2019; 25(1):40-50. PubMed ID: 30266308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the management of elderly patients with non-small-cell lung cancer.
    Blanco R; Maestu I; de la Torre MG; Cassinello A; Nuñez I
    Ann Oncol; 2015 Mar; 26(3):451-63. PubMed ID: 25060421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life.
    Pottel L; Lycke M; Boterberg T; Pottel H; Goethals L; Duprez F; Van Den Noortgate N; De Neve W; Rottey S; Geldhof K; Buyse V; Kargar-Samani K; Ghekiere V; Debruyne PR
    Eur J Cancer Care (Engl); 2014 May; 23(3):401-12. PubMed ID: 24467393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.
    Chen L; Huang J; Wu W; Ta S; Xie X
    Int J Cardiovasc Imaging; 2019 Jun; 35(6):1009-1017. PubMed ID: 30941563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).
    Tucci A; Martelli M; Rigacci L; Riccomagno P; Cabras MG; Salvi F; Stelitano C; Fabbri A; Storti S; Fogazzi S; Mancuso S; Brugiatelli M; Fama A; Paesano P; Puccini B; Bottelli C; Dalceggio D; Bertagna F; Rossi G; Spina M;
    Leuk Lymphoma; 2015 Apr; 56(4):921-6. PubMed ID: 25110825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.